Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses

BACKGROUND: The anti‐tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors. Breakthrough bleeds while on concizumab prophylaxis may be treated with bypassing agents (recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjalke, Marianne, Kjelgaard‐Hansen, Mads, Andersen, Søren, Hilden, Ida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360123/
https://www.ncbi.nlm.nih.gov/pubmed/33819375
http://dx.doi.org/10.1111/jth.15323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360123/
https://www.ncbi.nlm.nih.gov/pubmed/33819375
http://dx.doi.org/10.1111/jth.15323

Ejemplares similares